Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy
Rory M. Shallis, Maximilian Stahl, Wei Wei, Pau Montesinos, Étienne Lengliné, Judith Neukirchen, Vijaya Raj Bhatt, Mikkael A. Sekeres, Amir T. Fathi, Heiko Konig, Selina M. Luger, Irum Khan, Gail J. Roboz, Thomas Cluzeau, David Martínez‐Cuadrón, Emmanuel Raffoux, Ulrich Germing, Jayadev Manikkam Umakanthan, Sudipto Mukhereje, Andrew M. Brunner, Adam M. Miller, Christine M. McMahon, Ellen K. Ritchie, Rebeca Rodríguez‐Veiga, Raphaël Itzykson, Blanca Boluda, Florence Rabian, Mar Tormo, Evelyn Acuña‐Cruz, Emma Rabinovich, Brendan Yoo, Isabel Cano, Nikolai A. Podoltsev, Jan Philipp Bewersdorf, Steven D. Gore, Amer M. Zeidan
Abstract
Acute myeloid leukemia (AML) is frequently associated with hyperleukocytosis [white blood cell count (WBC) of >50 or >100 × 109/L at presentation] [1]. Hyperleukocytosis also predicts a higher risk...